ArticleHaematologica2019

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Simon T Durrant et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.